Together we Drive the Future

Complementary & Companion Diagnostics in Oncology

EARLY BIRD DISCOUNT! Register by Jul 07, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!

registration button

Cancer Therapeutics & Partnering Summit

Oncology Partnering & Deal-Making

Cancer Immunotherapy

Complementary & Companion Diagnostics in Oncology

Subscribe for updates

Dear Colleague,

Cancer Diagnostics have become fully ingrained in modern cancer treatment programs, and will continue to have an expanding role. Liquid biopsy approaches could exceed imaging in both sensitivity and specificity and yield more information on the tumor. The need for diagnostics for guiding immunotherapy is clear. Precision drug treatment and personal vaccines require a high resolution diagnostic of each tumor.

Technological advances have provided new levels of sensitivity that allow biomarker evaluation in the circulation, expanding the diversity of biomarker targets and facilitating time-based monitoring. In addition, information from the growing array of approaches has identified relevant molecules for targeted drug design. Together, these have facilitated a more intelligent approach to the development of therapy and its delivery to the cancer patient.

We invite you to attend the Complementary & Companion Diagnostics Conference, which will take place September 28-29, 2017 in San Diego, CA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss new research in cancer diagnostics, including next generation sequencing, the use of clinical utility of cell-free DNA liquid biopsy, patient selection for cancer drug development, and correlative predictive markers.

Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for the Future

Complementary & Companion Diagnostics in Oncology
I. Next Generation Sequencing in Cancer Diagnosis
II. Liquid Biopsy for Cancer Detection & Monitoring
III. Genomic Biomarkers in Immunotherapy
IV. Case Studies for Development & Commercialization


We hope to see you there! 

Best regards,

The 2017 Advisory Committee